On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Public comments close June 29. If finalized, large-scale compounding of these medications would end — even during future shortages.
What This Means for Your Current Prescription
Nothing changes immediately. The comment period runs through June 29, and any final rule would take months to implement. If you currently have a compounded GLP-1 prescription, continue taking it as prescribed. Your existing supply and refills are not affected by a proposal.
The Distinction That Matters
The proposal targets 503B outsourcing facilities — large-scale batch compounders that supply many telehealth platforms. 503A pharmacies (patient-specific compounders) are regulated differently and may be less directly affected. However, the regulatory signal puts pressure on the entire compounding market.
Planning Ahead
If you want to hedge against regulatory changes, consider providers that offer both compounded and brand-name pathways. If compounded options become restricted, having an existing relationship with a provider that can pivot to brand-name prescriptions (with insurance coordination) gives you continuity.
Sesame Care From $99/visit · Prescribes FDA-approved brand-name medications only. Accepts insurance. No subscription lock-in.
Prescribes FDA-approved brand-name medications only.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.